StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Vikas Sethi, Sethi Finmart

BUYZydus Lifesciences Limited

byVikas Sethi, Sethi FinmartHorizon: NA (inferred Intraday)28 Sept 2026, 8:47 am ISTvia Zee Business (Live)

Entry₹1,210.7Inferred
Target₹1,230
Total upside +1.59% (call closed)
Stop loss₹1,190-1.71% risk
At expiry₹1,213.428 Sept 2026, 3:05 pm
Expired+0.22%
Follow Vikas Sethi for new calls(42% target hit, 64 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 29 Sept, 1:34 am IST
3 supporting1 neutral0 opposing
Supports the BUY call (3)

3 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·28 Sept · today

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · 2d ago

(opens in new tab)

The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.

BSE · Company Update·26 Sept · 2d ago

(opens in new tab)
Neutral / worth noting (1)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 3d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.